Peptide T (original) (raw)
Peptide T is an HIV entry inhibitor discovered in 1986 by Candace Pert and Michael Ruff, a US neuroscientist and immunologist. Peptide T, and its modified analog Dala1-peptide T-amide (DAPTA), a drug in clinical trials, is a short peptide derived from the HIV envelope protein gp120 which blocks binding and infection of viral strains which use the CCR5 receptor to infect cells.
| Property | Value |
|---|---|
| dbo:abstract | Peptide T is an HIV entry inhibitor discovered in 1986 by Candace Pert and Michael Ruff, a US neuroscientist and immunologist. Peptide T, and its modified analog Dala1-peptide T-amide (DAPTA), a drug in clinical trials, is a short peptide derived from the HIV envelope protein gp120 which blocks binding and infection of viral strains which use the CCR5 receptor to infect cells. Peptide T has several positive effects related to HIV disease and Neuro-AIDS. A FDG-PET neuro-imaging study in an individual with AIDS dementia who completed a 12-wk treatment with intranasal DAPTA, showed remission in 34 out of 35 brain regions after treatment. A placebo-controlled, three site, 200+ patient NIH-funded clinical trial, which focused on neurocognitive improvements, was conducted between 1990 and 1995. The results showed that DAPTA was not significantly different from placebo on the study primary end points. However, 2 of 7 domains, abstract thinking and speed of information processing, did show improvement in the DAPTA group (p<.05). Furthermore, twice as many DAPTA-treated patients improved, whereas twice as many placebo patients deteriorated (P=.02). A sub-group analysis showed that DAPTA had a treatment effect and improved global cognitive performance (P=.02) in the patients who had more severe cognitive impairment. An analysis of antiviral effects from the 1996 NIH study showed peripheral viral load (combined plasma and serum) was significantly reduced in the DAPTA-treated group. An eleven-person study for peptide T effects on cellular viral load showed reductions in the persistently infected monocyte reservoir to undetectable levels in most of the patients. Elimination of viral reservoirs, such as the persistently infected monocytes or brain microglia, is an important treatment goal. Peptide T clinical development was stopped due to the propensity of the liquid nasal spray to lose potency upon storage and shifted to its shorter oral analog, the pentapeptide CCR2/CCR5 antagonist RAP-103 (Receptor Active Peptide) for neuropathic pain and neurodegeneration. RAP-103 also blocks CCR8, which may be important in neuropathic pain. Inhibitors of CCR5, including DAPTA, prevent and reverse neurodegeneration and are therapeutic targets in stroke/brain injury and dementia, such as in Parkinsons Disease. (en) |
| dbo:iupacName | (L)-Alanyl-(L)-seryl-(L)-threonyl-(L)-threonyl-(L)-threonyl-(L)-asparaginyl-(L)-tyrosyl-(L)-threonine (en) |
| dbo:thumbnail | wiki-commons:Special:FilePath/Peptide_T.svg?width=300 |
| dbo:wikiPageExternalLink | http://www.hastingsconlawquarterly.org/archives/V18/I3/Cohen.pdf |
| dbo:wikiPageID | 20097680 (xsd:integer) |
| dbo:wikiPageLength | 13319 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1101781241 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Candace_Pert dbr:Ron_Woodroof dbr:Entry_inhibitor dbr:Monocyte dbc:Entry_inhibitors dbr:Matthew_McConaughey dbr:Clinical_trial dbr:HIV dbr:HIV-associated_neurocognitive_disorder dbc:HIV/AIDS dbr:Dallas_Buyers_Club dbr:Alzheimer's_disease dbr:HIV/AIDS dbc:Peptides dbr:CCR5 dbr:Placebo dbr:Neurocognitive dbr:Gp120 |
| dbp:imagefile | Peptide T.svg (en) |
| dbp:imagesize | 250 (xsd:integer) |
| dbp:iupacname | (L)-Alanyl-(L)-seryl-(L)-threonyl-(L)-threonyl-(L)-threonyl-(L)-asparaginyl-(L)-tyrosyl-(L)-threonine (en) |
| dbp:wikiPageUsesTemplate | dbt:Chembox dbt:Chembox_Hazards dbt:Chembox_Identifiers dbt:Chembox_Properties dbt:Citation_needed dbt:Reflist dbt:Cascite dbt:Fdacite |
| dcterms:subject | dbc:Entry_inhibitors dbc:HIV/AIDS dbc:Peptides |
| gold:hypernym | dbr:Inhibitor |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q11173 yago:Abstraction100002137 yago:Amide114724264 yago:Chemical114806838 yago:Compound114818238 yago:Material114580897 yago:Matter100020827 yago:OrganicCompound114727670 yago:Part113809207 yago:Peptide114743046 yago:PhysicalEntity100001930 yago:Relation100031921 dbo:ChemicalCompound dbo:Drug yago:Substance100019613 yago:WikicatPeptides |
| rdfs:comment | Peptide T is an HIV entry inhibitor discovered in 1986 by Candace Pert and Michael Ruff, a US neuroscientist and immunologist. Peptide T, and its modified analog Dala1-peptide T-amide (DAPTA), a drug in clinical trials, is a short peptide derived from the HIV envelope protein gp120 which blocks binding and infection of viral strains which use the CCR5 receptor to infect cells. (en) |
| rdfs:label | Peptide T (en) |
| owl:sameAs | freebase:Peptide T yago-res:Peptide T wikidata:Peptide T http://azb.dbpedia.org/resource/پپتید_تی dbpedia-fa:Peptide T dbpedia-sh:Peptide T dbpedia-sr:Peptide T https://global.dbpedia.org/id/4tJH1 |
| prov:wasDerivedFrom | wikipedia-en:Peptide_T?oldid=1101781241&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Peptide_T.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:Peptide_T |
| is dbo:wikiPageRedirects of | dbr:Peptide_t |
| is dbo:wikiPageWikiLink of | dbr:Candace_Pert dbr:Ron_Woodroof dbr:Oligopeptide dbr:Dallas_Buyers_Club dbr:Peptide_t |
| is foaf:primaryTopic of | wikipedia-en:Peptide_T |
